2.31 +0.04 (1.75%)
KERX
Stock Details
Last Trade:2.31 Change:+0.04 (1.75%) Prev Close:2.27 Open: 2.28 Days Range:2.28 – 2.37 52 Week Range: 0.09 - 3.45 Volume:736057 P/E: 9.24EPS:0.25
View AllRecent Alerts 02/09/10
Recent Alert on 02/03/10 at 8:39am
Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401
Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. FDA regarding a Special Protocol Assessment on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in... Read More
Recent Alert on 02/03/10 at 8:39am
Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401
Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401
Recent Alert on 01/29/10 at 8:57am
Æterna Zentaris (AEZS) and Partner Keryx Biopharma (KERX) Report on Phase 2 of Perifosine Waldenstrom's Macroglobulinemia Treatment
Æterna Zentaris (AEZS) and Partner Keryx Biopharma (KERX) Report on Phase 2 of Perifosine Waldenstrom's Macroglobulinemia Treatment
Recent Alert on 01/29/10 at 8:57am
Æterna Zentaris (AEZS) and Partner Keryx Biopharma (KERX) Report on Phase 2 of Perifosine Waldenstrom's Macroglobulinemia Treatment
Æterna Zentaris (AEZS) and Partner Keryx Biopharma (KERX) Report on Phase 2 of Perifosine Waldenstrom's Macroglobulinemia Treatment
Recent Alert on 01/29/10 at 8:36am
Keryx Biopharmaceuticals (KERX) Announes Positive Phase 2 Study of Perifosine
Keryx Biopharmaceuticals (KERX) Announes Positive Phase 2 Study of Perifosine
View AllRecent Press Releases
Press Release on 02/05/10 at 3:59pm
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Press Release on 02/05/10 at 6:50am
Biopharmaceutical Stock Alert for Keryx Biopharmaceuticals Inc. Issued by InvestorSoup
Biopharmaceutical Stock Alert for Keryx Biopharmaceuticals Inc. Issued by InvestorSoup
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 01/17/10 at 4:00am
Healthcare Conference Updates: Cytori, Auxilium, Keryx, Cell Therapeutics
Healthcare Conference Updates: Cytori, Auxilium, Keryx, Cell Therapeutics